维普期刊资源整合服务平台（V6.5）

50篇 您的检索式：作者名="Figg W d"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	hTERT-immortalized endothelial cells: an important new research tool显示文摘	PRICE D K FIGG W D	2004	Cell Cycle2004，3，6：	1
2	Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment 显示文摘	Gardner E R Dahut W Figg W D	2008	J Chromatogr B Analyt Technol Biomed Life Sci2008，862，：	1
3	The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer 显示文摘	Retter A S Figg W D Dahut W L	2003	Clin Prostate Cancer2003，2，3：	1
4	The influence of mycorrhizal symbiosis and fertilizer amendments on establishment of vegetation in heavy metal mine spoil显示文摘	Hetrick B A D Wilson G W T Figge D A H	1994	Environmental Pollution1994，86，2：	1
5	Angiogenesis inhibitors: current strategies and future prospects 显示文摘	COOK K M FIGG W D	2010	CA Cancer J Clin2010，60，4：	1
6	Micellar paclitaxel improves severe psoriasis in a prospective phase Ⅱ pilot study显示文摘	Ehrlich A Booher S Becerra Y Borris D L Figg W D Turner M L		0，，：	1
7	A framework for assessing the vulnerabil- --ity of food system to future shocks显示文摘	Fraser E D G Mabee W Figge F	2005	Fture2005，，37：	1
8	Thalidomide显示文摘	FRANKS M E MACPHERSON G R FIGG W D	2004	Lancet2004，263，9423：	1
9	A randomized phase Ⅱ trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer显示文摘	Figg W D Arlen P Gulley J	2001	Semin Oncol2001，28，415：	1
10	Recent advances in pharmacogenetic approaches to anticancer drug development 显示文摘	Smith N F Figg W D Sparreboom A	2004	Drug Development Research2004，62，：	1
11	Modulation of cytochrome P450 activity: implications for cancer therapy显示文摘	SCRIPTURE C D SPARREBOOM A FIGG W D	2005	Lancet Oncol2005，6，10：	1
12	Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy显示文摘	Scripture C D Figg W D Sparreboom A	2005	Ther Clin Risk Manag2005，1，2：	1
13	Combina- tion of bevacizumab and doeetaxel in doeetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study显示文摘	DI LORENZO G FIGG W D FOSSA S D	2008	EurUro12008，54，5：	1
14	hTert-immortalized endothelial cells: an important new research tool 显示文摘	Price D K Figg W D	2004	Cell Cycle2004，3，6：	1
15	Combination of bevaci- zumab and docetaxel in docetaxel - - pretreated hormone-refractory prostate cancer : a phase 2 study 显示文摘	Di Lorenzo G Figg W D Fossa S D	2008	Eur Urol2008，54，5：	1
16	Interaction between Plastics Packaging Materials and Foodstuffs with Different Fat Content and Fat Release Properties显示文摘	BIEBER W D FIGGE K KOCH J	1985	Food Additives and Contaminants1985，，2：	1
17	A randomized phase Ⅱ trial of thalidomide,an angiogenesis inhibitor,in patients with androgen-independent prostate cancer显示文摘	Figg W d Dahut W Duray P	2001	Clin Cancer Res2001，7，7：	1
18	A doub- le-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation显示文摘	FIGG W D HUSSAIN M H GULLEY J L	2009	J Urol2009，181，3：	1
19	Modulation of cytochrome P450 activity: implications for cancer therapy 显示文摘	SCRIPTURE C D SPARREBOOM A FIGG W D	2005	Lancet Oncol2005，6，10：	1
20	Pre-clinieat and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer 显示文摘	FIGG W D LI H SISSUNG T	2007	BJU Int2007，99，5：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示